BACKGROUND: [(18)F]fluorodeoxyglucose positron emission tomography (PET) is a useful staging investigation for follicular lymphoma (FL). Recent studies have shown that positive post-treatment PET is also a strong predictor of inferior overall survival. PURPOSE: To evaluate the predictive value of mid- and post-treatment PET in FL patients with respect to progression-free survival (PFS) and overall survival (OS). METHODS: We included 57 patients with indolent FL (grade 1, 2, and 3a) who received induction chemotherapy. Mid- and post-treatment PET results were correlated with PFS and OS retrospectively and analysed using Kaplan-Meier survival analysis and Cox regression. RESULTS: Post-treatment PET was predictive of OS (mean OS 95.2 vs. 45.0 months for PET-negative vs. PET-positive, p < 0.001) and showed a trend towards significance for PFS (mean PFS 74.4 vs. 38.2 months for PET- vs. PET+, p = 0.083). 3-year PFS for post-treatment PET- and PET+ patients were 72 and 30 %, respectively. 3-year OS were 96 and 60 %, respectively. Mid-treatment PET was not predictive of PFS (mean PFS 78.5 vs. 51.0 months for PET- vs. PET+, p = 0.35) nor OS (mean OS 89.9 vs. 76.6 months for PET- vs. PET+, p = 0.92). CONCLUSION: Post-treatment PET is predictive of OS in indolent FL. It identifies patients who might benefit from more intensive follow-up, enrolment in clinical trials or second-line therapy. Mid-treatment PET scan results did not appear to predict long-term treatment outcomes.
BACKGROUND:[(18)F]fluorodeoxyglucose positron emission tomography (PET) is a useful staging investigation for follicular lymphoma (FL). Recent studies have shown that positive post-treatment PET is also a strong predictor of inferior overall survival. PURPOSE: To evaluate the predictive value of mid- and post-treatment PET in FL patients with respect to progression-free survival (PFS) and overall survival (OS). METHODS: We included 57 patients with indolent FL (grade 1, 2, and 3a) who received induction chemotherapy. Mid- and post-treatment PET results were correlated with PFS and OS retrospectively and analysed using Kaplan-Meier survival analysis and Cox regression. RESULTS: Post-treatment PET was predictive of OS (mean OS 95.2 vs. 45.0 months for PET-negative vs. PET-positive, p < 0.001) and showed a trend towards significance for PFS (mean PFS 74.4 vs. 38.2 months for PET- vs. PET+, p = 0.083). 3-year PFS for post-treatment PET- and PET+ patients were 72 and 30 %, respectively. 3-year OS were 96 and 60 %, respectively. Mid-treatment PET was not predictive of PFS (mean PFS 78.5 vs. 51.0 months for PET- vs. PET+, p = 0.35) nor OS (mean OS 89.9 vs. 76.6 months for PET- vs. PET+, p = 0.92). CONCLUSION: Post-treatment PET is predictive of OS in indolent FL. It identifies patients who might benefit from more intensive follow-up, enrolment in clinical trials or second-line therapy. Mid-treatment PET scan results did not appear to predict long-term treatment outcomes.
Authors: Sun Ha Boo; Joo Hyun O; Soo Jin Kwon; Ie Ryung Yoo; Sung Hoon Kim; Gyeong Sin Park; Byung Ock Choi; Seung Eun Jung; Seok-Goo Cho Journal: Nucl Med Mol Imaging Date: 2019-06-29
Authors: Yeye Zhou; Zixuan Zhao; Yiwei Wu; Jihui Li; Bin Zhang; Shibiao Sang; Shengming Deng Journal: Cancer Manag Res Date: 2019-07-23 Impact factor: 3.602
Authors: Raja Shanker; Syed Ziauddin Ahmed Zaidi; Nawal Faiez AlShehry; Fahad AlGhmlas; Ibraheem Hussein Motabi; Shahid Iqbal; Ahmad Ali Butt; Hassan AlShehri; Imran Khan Tailor; Syed Yasir Altaf; Mubarak AlGhamdi; Mohammed Marie; Mansour AlFayez; Kamal Al Zahrani; Mohammed Dwaimah; Tahani Al-Halouli; Wafaa Al-Shakweer; Maied Zaher AlShehery; Abdul Rehman Zia Zaidi; Atta Munawar Gill; Belal Mohammed Albtoosh; Musab Ahmed Journal: JMIR Form Res Date: 2021-11-12